FEB 18, 2014
Glaucoma, IOP and Aqueous Flow, Medical Therapy
In this interview, Dr. Joel Schuman introduces ROCK inhibitors, a new class of drugs that lower IOP by inhibiting Rho-kinase (ROCK) and thus increase outflow through the trabecular meshwork. Because ROCK inhibitors and prostoglandins act through unique pathways, Dr. Schuman believes drugs from each class can be used in concert to an additive effect. Several ROCK inhibitors, including ROCK/NET which also limits norepinephrine transporter (NET), are primed to enter late-phase clinical trials.